RxDoctor Payments Data

John Sweeney, MD

Gastroenterology · Winston Salem, NCNPI 1427162320

Payments from drug & device makers

$2,258in general payments, 2019–2025

Across 111 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$352
  • Johnson & Johnson$345
  • AbbVie$308
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$280
  • Fujifilm Healthcare Americas Corporation$241
  • Boston Scientific$99
  • plus $634 from 21 others

What the payments were for

  • Food & beverage$1,93286%
  • Education$854%
  • Gifts$1507%
  • Other$914%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,258 in reported general payments places this provider in the 45th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$110,689
Medicare patients
340
Services billed
1,734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase71$168,637
XifaxanRifaximin42$129,658
LinzessLinaclotide100$65,573
CreonLipase/Protease/Amylase15$46,994
Dexlansoprazole DrDexlansoprazole47$18,902
Omeprazole331$7,601
Mesalamine14$6,814
Lansoprazole25$4,425
Famotidine233$4,203
Esomeprazole Magnesium117$3,582
Lubiprostone15$3,461
Pantoprazole Sodium238$3,244
Dicyclomine Hcl157$2,982
CholestyramineCholestyramine (With Sugar)31$2,381
SutabSod Sulf/Pot Chloride/Mag Sulf13$2,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$280$129,65842 claims
AbbVieLinzess, Creon$308$112,567115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →